scholarly journals Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?

2018 ◽  
Vol 10 (S26) ◽  
pp. S3203-S3206
Author(s):  
Mohammed Amine Achhal El Kadmiri ◽  
Arun Rajan
Keyword(s):  
Lung Cancer ◽  
Early Intervention ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Small Cell ◽  
Small Cell Lung ◽  
Neoadjuvant Immunotherapy

scholarly journals Important Surgical and Clinical Endpoints in Neoadjuvant Immunotherapy Trials in Resectable Non-Small Cell Lung Cancer

2021 ◽  
pp. 100221
Author(s):  
Jay M. Lee ◽  
Anthony W. Kim ◽  
Tomasz Marjanski ◽  
Pierre-Emmanuel Falcoz ◽  
Masahiro Tsuboi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Clinical Endpoints ◽  
Neoadjuvant Immunotherapy

scholarly journals Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer

2021 ◽  
Vol 33 (2) ◽  
pp. 203-215
Author(s):  
Hanfei Guo ◽  
◽  
Wenqian Li ◽  
Lei Qian ◽  
Jiuwei Cui
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Neoadjuvant Immunotherapy

O-253 Early intervention with epoetin alfa maintains hemoglobin (HB) in advanced non-small-cell lung cancer (NSCLC) patients

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S74 ◽  
Author(s):  
Robert Milroy ◽  
Giorgio Scagliotti ◽  
Paulus Martin van den Berg ◽  
Nikolaos E. Galanis ◽  
Ramón García Gómez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Intervention ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Epoetin Alfa ◽  
Small Cell Lung ◽  
Nsclc Patients

scholarly journals In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients

Cancers ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1271 ◽  
Author(s):  
Heeke ◽  
Benzaquen ◽  
Long-Mira ◽  
Audelan ◽  
Lespinet ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutational Burden ◽  
Potential Biomarker ◽  
Tumor Mutational Burden ◽  
Melanoma Patients

Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer (NSCLC). However, its in-house assessment in routine clinical practice is currently challenging and validation is urgently needed. We have analyzed sixty NSCLC and thirty-six melanoma patients with ICI treatment, using the FoundationOne test (FO) in addition to in-house testing using the Oncomine TML (OTML) panel and evaluated the durable clinical benefit (DCB), defined by >6 months without progressive disease. Comparison of TMB values obtained by both tests demonstrated a high correlation in NSCLC (R2 = 0.73) and melanoma (R2 = 0.94). The association of TMB with DCB was comparable between OTML (area-under the curve (AUC) = 0.67) and FO (AUC = 0.71) in NSCLC. Median TMB was higher in the DCB cohort and progression-free survival (PFS) was prolonged in patients with high TMB (OTML HR = 0.35; FO HR = 0.45). In contrast, we detected no differences in PFS and median TMB in our melanoma cohort. Combining TMB with PD-L1 and CD8-expression by immunohistochemistry improved the predictive value. We conclude that in our cohort both approaches are equally able to assess TMB and to predict DCB in NSCLC.

scholarly journals Perioperative considerations for neoadjuvant immunotherapy in non–small cell lung cancer

2020 ◽  
Vol 160 (5) ◽  
pp. 1376-1382 ◽  
Author(s):  
Brendon M. Stiles ◽  
Boris Sepesi ◽  
Stephen R. Broderick ◽  
Matthew J. Bott
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Neoadjuvant Immunotherapy

The limited clinical benefit of respiration gated radiotherapy (RGRT) in non-small cell lung cancer (NSCLC)

Lung Cancer ◽  
2010 ◽  
Vol 67 ◽  
pp. S30-S31 ◽  
Author(s):  
R. Muirhead ◽  
C. Featherstone ◽  
A. Duffton ◽  
K. Moore ◽  
S. McNee
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Small Cell ◽  
Small Cell Lung ◽  
Gated Radiotherapy

RAD51Bme as predictive biomarker for PD-1 blockade response in non-small cell lung cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15235-e15235
Author(s):  
Inês Maria Guerreiro ◽  
Daniela Barros-Silva ◽  
Paula Lopes ◽  
Ana Luísa Cunha ◽  
João Lobo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Checkpoint Inhibitors ◽  
Predictive Biomarkers ◽  
Predictive Biomarker ◽  
Small Cell ◽  
Small Cell Lung ◽  
Dna Repair Gene

e15235 Background: Lung cancer (LC) cells frequently express high levels of programmed death-ligand 1 (PD-L1). Although these levels grossly correlate with likelihood of response to specific checkpoint inhibitors, prediction of response is rather imperfect and, thus, more accurate predictive biomarkers are mandatory. We examined the methylation profile of RAD51B, a DNA-repair gene, as candidate predictive biomarker for efficacy of anti-PD-1 therapy in patients with non-small cell lung cancer (NSCLC), correlating with patients’ outcome. Methods: PD-L1 immunoexpression and RAD51Bme levels were analysed in samples of NSCLC obtained from patients not treated with anti-PD-1 blockade (testing cohort) and patients treated with anti-PD-1 (validation cohort). Results: Of a total of 127 patients assessed, 58.3% depicted positivity for PD-L1 (PD-L1+). RAD51Bme levels significantly associated with PD-L1 immunoexpression. Patients with clinical benefit from immunotherapy disclosed higher RAD51Bme levels (p = 0.04) and significantly higher median progression free survival (PFS) (p = 0.02). PD-L1+ was also associated with longer overall survival (p = 0.03). Conclusions: We demonstrated that RAD51Bme levels might be combined with validated predictive biomarker PD-L1 immunostaining to select patients who will most likely experience clinical benefit from PD-1 blockade. The predictive value of RAD51Bme should be confirmed in prospective studies.

Sign in / Sign up

Export Citation Format

Share Document